Abstract
The therapeutic potential of cannabinoids has been studied and investigated through centuries, although many interesting discoveries have emerged from this field in the past decades. Indeed, peripheral analgesic effects of cannabinoids are a new avenue of treatment since they are avoiding the deleterious central side effects of systemic administration. Recently, it has been demonstrated that cannabinoid receptors (more specifically CB1 and CB2 receptors) and their endogenous ligands are present at the peripheral level, especially in different layers of skin, and mostly, in the epidermis and dermis. Those findings are reinforcing and confirming the efficacy of peripheral administration of cannabinoids used to alleviate pain in many different animal models. However, many studies have shown that the endocannabinoid system interacts with other receptors and pathways to modulate pain at the peripheral level. Thereof, the main goal of this review is to explain, in a better way, the different interactions regarding the cannabinoid system with other cellular components of its environment, its involvement in the modulation of pain at the peripheral level and, more precisely, in different layers of the skin.
Keywords: Cannabinoids, endocannabinoids, anandamide, primary afferent neurone, analgesia, pain, opioids
Current Molecular Pharmacology
Title: The Role of the Endogenous Cannabinoid System in Peripheral Analgesia
Volume: 2
Author(s): Josee Guindon and Pierre Beaulieu
Affiliation:
Keywords: Cannabinoids, endocannabinoids, anandamide, primary afferent neurone, analgesia, pain, opioids
Abstract: The therapeutic potential of cannabinoids has been studied and investigated through centuries, although many interesting discoveries have emerged from this field in the past decades. Indeed, peripheral analgesic effects of cannabinoids are a new avenue of treatment since they are avoiding the deleterious central side effects of systemic administration. Recently, it has been demonstrated that cannabinoid receptors (more specifically CB1 and CB2 receptors) and their endogenous ligands are present at the peripheral level, especially in different layers of skin, and mostly, in the epidermis and dermis. Those findings are reinforcing and confirming the efficacy of peripheral administration of cannabinoids used to alleviate pain in many different animal models. However, many studies have shown that the endocannabinoid system interacts with other receptors and pathways to modulate pain at the peripheral level. Thereof, the main goal of this review is to explain, in a better way, the different interactions regarding the cannabinoid system with other cellular components of its environment, its involvement in the modulation of pain at the peripheral level and, more precisely, in different layers of the skin.
Export Options
About this article
Cite this article as:
Guindon Josee and Beaulieu Pierre, The Role of the Endogenous Cannabinoid System in Peripheral Analgesia, Current Molecular Pharmacology 2009; 2 (1) . https://dx.doi.org/10.2174/1874467210902010134
DOI https://dx.doi.org/10.2174/1874467210902010134 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meiotic Recombination in Plants
Current Genomics Incomplete Invention of Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Melanogenesis and Melanosome Transportation Modulators from Medicinal Plants
Letters in Drug Design & Discovery Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Current Pharmaceutical Design Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Major Drugs Used in COVID-19 Treatment: Molecular Mechanisms, Validation and Current Progress in Trials
Coronaviruses Possible Pathogenic Role of the Transmembrane Isoform of CD160 NK Lymphocyte Receptor in Paroxysmal Nocturnal Hemoglobinuria
Current Molecular Medicine Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Editorial (Thematic Issue: Structure and Function of Proteins)
Protein & Peptide Letters HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Modulation of 3,4-Methylenedioxymethamphetamine Effects by Endocannabinoid System
Current Pharmaceutical Design Anti-HIV Inhibitors Based on Nucleic Acids: Emergence of Aptamers as Potent Antivirals
Current Drug Targets - Infectious Disorders Leptin in Thrombosis and Atherosclerosis
Current Pharmaceutical Design Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Editorial A New Year of Excellence
Current Molecular Medicine